Search results
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
Zacks via Yahoo Finance Canada· 15 hours agoInvestors should also note any recent changes to analyst estimates for Johnson & Johnson. Such...
Johnson & Johnson: An Exploration into Its Intrinsic Value
GuruFocus.com via Yahoo Finance Canada· 3 days agoIt does not formulate a recommendation to purchase or divest anystock and does not consider...
Why Johnson Controls (JCI) is Poised to Beat Earnings Estimates Again
Zacks via Yahoo Finance Canada· 2 days agoJohnson Controls (JCI) has an impressive earnings surprise history and currently possesses the right...
Lilly beefs up bowel disease drug portfolio with $3.2 billion Morphic deal
AOL· 3 days agoShares of Waltham, Massachusetts-based Morphic surged 76% to $56.15 in premarket trading on Lilly's offer of $57 per share, which represents a 79% premium to stock ...
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
Zacks via Yahoo Finance Canada· 6 days agoA new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However,...
CFO Resigns At Chinese Electric Vehicle Maker Nio
Baystreet· 6 days agoChinese electric vehicle maker Nio (NIO) has announced that its long-time chief financial officer (CFO) Steven Wei Feng has resigned effective...
Finding Trades For The Biggest Names Left On The NBA Trade Market
UPROXX· 2 days agoFour star wings are very much available, so we tried to find what trade packages might be out there...
Markets on alert for Biden exit as Trump-win trades mount
National Post· 7 days agoThe recalibration of portfolios kicked off at the end of last week after Biden’s disastrous debate...
Eli Lilly to buy bowel disease drug developer Morphic for US$3.2-billion
The Globe and Mail· 3 days agoShares of drug developer Morphic surged 76 per cent to $56.15 premarket on Lilly’s offer of $57 per...
Stocks Are on a Record-Setting Tear. Where They Go From Here and 4 Other Things to Know Today.
Barrons.com· 2 days agoSouthwest rebuffs activist Elliott’s threat to appeal directly to shareholders, Eli Lilly is buying...